Mostrando 10 resultados de: 23
Filtros aplicados
Área temáticas
Farmacología y terapéutica(17)
Enfermedades(13)
Bioquímica(9)
Fisiología humana(6)
Medicina y salud(5)
Área de conocimiento
Genética(16)
Farmacología(8)
Psicopatología(4)
Pediatría(1)
Trastorno depresivo mayor(1)
Origen
scopus(23)
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population
ArticleAbstract: Risperidone non-compliance is often high due to undesirable side effects, whose development is in paPalabras claves:Adverse events, Antipsychotic, pharmacogenetics, RisperidoneAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusA combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances
ArticleAbstract: This study examined, for the first time, whether a high CYP2D6-CYP2C19 metabolic capacity combinatioPalabras claves:Autores:Adrián LLerena, Blasco-Fontecilla H., Courtet P., Delgado A., Guillaume S., Jaussent I., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards
ArticleAbstract: Earlier we had found that the CYP2C9*2 allelic frequency was lower in Mexican-Americans living in CaPalabras claves:CYP2C9, Hispanics, Mexican-Americans, Mexican-Mestizos, Mexican-Tepehuanos, pharmacogeneticsAutores:Adrián LLerena, Alanis-Bãuelos R.E., Dorado P., Lares-Asseff I., Licinio J., Penãs-Lledó E.M., Sosa-Macías M.G., Wong M.L.Fuentes:scopusCYP2C9 gene and susceptibility to major depressive disorder
ArticleAbstract: Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disPalabras claves:CYP2C9 gene, Depression, SchizophreniaAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusCYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
ArticleAbstract: We aimed to explore the possible influence of CYP2C9 (∗2, ∗3 and IVS8-109 A>T), CYP2C19 (∗2, ∗3 andPalabras claves:Autores:Adrián LLerena, Dorado P., Familiar-López I., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
ArticleAbstract: CYP2D6 genotype and debrisoquine metabolic ratio (MR) were analyzed in 133 Nicaraguan Mestizos (NMs)Palabras claves:Cubans, CYP2D6, debrisoquine hydroxylation, Latinos, Nicaraguans, PhenotypeAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusCYP2D6 polymorphism in patients with eating disorders
ArticleAbstract: CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is,Palabras claves:CYP2D6, Eating disorders, pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Agüera Z., Dorado P., Estivill X., Fernández‐aranda F., Gratacòs M., Penãs-Lledó E.M.Fuentes:scopusGenetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative
ArticleAbstract: We present allele frequencies involving 39 pharmacogenetic biomarkers studied in Brazil, and their dPalabras claves:Autores:Adrián LLerena, Andrade P.X.C., Aquino M.M., Céspedes-Garro C., Horta B.L., Kehdy F.S.G., Lima-Costa M.F., Mauricio L. Barreto, Pereira A.C., Rodrigues-Soares F., Sampaio-Coelho J., Tarazona-Santos E.M., Zolini C.Fuentes:scopusNeurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: Influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms
ArticleAbstract: Pharmacogenetic studies have shown that genetic defects in drug-metabolizing enzymes encoded by CYP2Palabras claves:CYP2C19, CYP2C9, Epilepsy, Neurological toxicity, paediatric, PhenytoinAutores:Adrián LLerena, Dorado P., López-Torres E., Martínez-Antón J., Penãs-Lledó E.M.Fuentes:scopusHigh frequency and founder effect of the CYP3A4∗20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
ArticleAbstract: Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have beenPalabras claves:Autores:Adrián LLerena, Apellániz-Ruiz M., Carracedo Á., Cascón A., Comino-Méndez I., Currás-Freixes M., De Cubas A.A., Grazina M., Ingelman-Sundberg M., Inglada-Pérez L., Mancikova V., Moya G.E., Naranjo M.E.G., Opocher G., Rasool M., Rebai A., Robledo M., Rodríguez-Antona C., Sánchez L., Taboada-Echalar P., Triki S.Fuentes:scopus